Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WG1025 topical gene therapy in dystrophic epidermolysis bullosa (Phase I/II and extension)
ChiCTR2400084208Phase 2Recruiting
- Sponsor
- Southern Medical University Dermatology Hospital
- Start
- Feb 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of WG1025 in dystrophic epidermolysis bullosa (DEB) (4 arms), sponsored by Southern Medical University Dermatology Hospital. Primary endpoints: Phase I: Incidence of treatment-emergent adverse events (TEAEs) by week 5, Phase I: Changes in safety parameters by week 5 and 1 more. Started Feb 2024; status: recruiting.
02
Drugs
WG1025
03
Conditions
dystrophic epidermolysis bullosa (DEB)
Beyond the preview
Go deeper on ChiCTR2400084208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084208.